ERBB2 and breast carcinoma: Employing MTI-31 and earlier mTOR-KIs, we further demonstrated that the profound antitumor efficacy of the mTOR-KIs is dependent on cancer driver mutation status of the tumors and involves molecular regulation of apoptotic machinery and lipid metabolism in HER2+/PIK3CAmut breast cancer.